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ARTICLE
Eradication of unresectable liver metastasis
through induction of tumour specific energy
depletion
Da Huo1, Jianfeng Zhu1, Guojun Chen2,3, Qian Chen2,3, Chao Zhang1, Xingyu Luo1, Wei Jiang1, Xiqun Jiang 4,
Zhen Gu 2,3 & Yong Hu 1
Treatment of liver metastasis experiences slow progress owing to the severe side effects. In
this study, we demonstrate a strategy capable of eliminating metastatic cancer cells in a
selective manner. Nucleus-targeting W18O49 nanoparticles (WONPs) are conjugated to
mitochondria-selective mesoporous silica nanoparticles (MSNs) containing photosensitizer
(Ce6) through a Cathepsin B-cleavable peptide. In hepatocytes, upon the laser irradiation, the
generated singlet oxygen species are consumed by WONPs, in turn leading to the loss of
their photothermally heating capacity, thereby sparing hepatocyte from thermal damage
induced by the laser illumination. By contrast, in cancer cells, the cleaved peptide linker
allows WONPs and MSNs to respectively target nucleus and mitochondria, where the
therapeutic powers could be unleashed, both photodynamically and photothermally. This
ensures the energy production of cancer cells can be abolished. We further assess the
underlying molecular mechanism at both gene and protein levels to better understand the
therapeutic outcome.
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Among various organs, liver is the most common site forcolonization of cancer cells, resulting in a high incidenceof liver metastasis and a high risk of cancer-related
death1–3. So far, surgery is the most effective approach in hand-
ling liver metastasis in the clinic2. Unfortunately, most cases of
liver metastases are diagnosed at the late stage when surgical
means is no longer effective. The case grows even worse for
diffusive liver metastasis (DLM) as characterized by the presence
of multiple metastasis nodules4. As an organ responsible for
intense metabolic activities, the liver itself is highly vulnerable to
complications associated with chemotherapeutics, thereby dam-
pening the survival benefits brought by chemotherapy5,6. Some of
the emerging therapeutics, such as iniparib and niraparib, are
capable of attenuating only cancer cells carrying unique genomic
feature by harnessing the mechanism named synthetic lethality7.
Though helpful to some extent, no success has been witnessed in
the case of liver metastasis yet. Besides, the precision down to
molecule level can, in turn, become a drawback for lacking a
potential of general application8. As such, it is still an urgent task
to develop an effective approach to extend the lifespan of DLM-
suffering patients.
By virtue of the fact that nanomaterials could favorably accu-
mulate in the liver after their blood entry8–13, nanomedicine is
now growingly recognized as a promising weapon against liver
abnormities14–16. The introduction of targeting moieties was
expected to promote nanomaterials’ enrichment in diseased
sites17–22. However, targeting specific biomarkers only allows a
certain portion of patients to benefit from the therapeutic23. To
manage pathologically distinct cancers, approach targeting more
universal features should be developed. Here, we focus on the
energy machinery of cancer cells24,25. On top of biogenesis stands
the ATP (adenosine triphosphate) as the fuel. Initial attempts of
blocking glycolysis (GLY)-related pathways were made given the
metabolic preference of cancer cells toward GLY over oxidative
phosphorylation (OXPHOS). Such a phenomenon is referred to
as Warburg effect26. Now, it is clear that some intermediates
produced during GLY are behind the metabolic shift to GLY26–29.
The OXPHOS can undergo a compensatory activation once GLY
is inhibited in an effort to rescue the stressed cancer cells26. To
conquer a tumour, concurrent inhibition of OXPHOS and GLY
activities is necessary. Meanwhile, as normal cells also rely on
OXPHOS to support their homeostasis, it is practically challen-
ging to confine the action only to cancer cells.
In this study, we proposed to selectively eliminate metastatic
cancer cells through energy depletion. A hybrid system composed
of photosensitizer (Ce6)-encapsulated mesoporous silica nano-
particle (MSN) and W18O49 nanoparticles (WONPs) was syn-
thesized. As shown in Fig. 1a, the MSNs and WONPs were
functionalized with triphenyl phosphonium (TPP) and nuclear
localization sequence (NLS), respectively, which allow their
selective binding with mitochondria30 and nucleus31. The
nucleus-targeting WONPs (Nuc(T)) were next covalently con-
jugated to mitochondria-targeting MSNs (Mito(T)) via a peptide
cleavable by Cathepsin B (final product denoted by Mito(T)-pep-
Nuc(T)), whose expression is aberrantly high in a variety of
cancers32. As illustrated in Fig. 1b, in cancer cells, Mito(T)-pep-
Nuc(T) is expected to rupture in the Cathepsin B-rich lysosomes,
liberating Mito(T) and Nuc(T) with distinct subcellular destina-
tions. Afterward, the laser irradiations are applied (633 nm
followed by 1064 nm) to sequentially trigger the photodynamic
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therapy (PDT) and photothermal therapy (PTT) mediated by Ce6
and WONPs, respectively. Both organelles could be destroyed,
collectively abolishing the ATP supply. Meanwhile, the peptide
linker stays intact in hepatocytes due to the insufficient Cathepsin
B activity. Upon 633-nm laser irradiation, the generated singlet
oxygen could be stoichiometrically consumed by WONPs,
thereby turning them into photothermally inert WO3 and abol-
ishing the heat generation upon 1064-nm laser exposure. As such,
the hepatocytes could be rescued from the destruction caused by
both PDT and PTT.
Results
Synthesis of the platform and the optimization. The MSNs were
synthesized following a published protocol33 featuring homo-
geneous pores with a mean diameter of 2.3 nm (Supplementary
Fig. 1). The WONPs were synthesized according to our previous
publication34,35, followed by their conjugation onto MSN that
contributes to a planet–satellite-like structure (Supplementary
Fig. 2). Enlargement in size was confirmed by dynamic light
scattering (DLS, Supplementary Fig. 3) analysis. The mean Zeta-
potential (Supplementary Fig. 4) decreased slightly from 36.7 to
28.7 mV for APTES- and peptide-functionalized MSNs,
respectively, and drastically decreased to −3.9 mV post WONPs
conjugation, possibly owing to the presence of carboxyl group in
WONPs. Afterward, we analyzed the enzymatic response of Mito
(T)-pep-Nuc(T). The resultant nanoparticles were incubated with
several enzymes and size changes were recorded by DLS analysis
(Supplementary Fig. 5). A noticeable size reduction can only be
observed in the presence of Cathepsin B (from 138.7 to 99.1 nm)
owing to the detachment of WONPs. This is further supported by
the TEM results (Supplementary Fig. 6), wherein the released
WONPs could be found. The content of tungsten in Mito(T)-
pep-Nuc(T) was assessed using inductively coupled plasma-mass
spectra (ICP-MS) before and after the enzyme challenge (Sup-
plementary Fig. 7). Exposure to Cathepsin B resulted in the
release of 93.7% of the anchored WONPs, whereas only 2.0%
liberation was found in the presence of Caspase 3 and MMP-2
(Supplementary Fig. 8).
Next, we optimized the formulation of Mito(T)-pep-Nuc(T). In
principle, the generated singlet oxygen species (SOS) should be
stoichiometrically consumed by WONPs. We used H2O2 as a
mimic of SOS. Ce6-free Mito(T)-pep-Nuc(T) was incubated with
different amounts of H2O2. We noticed that the introduction of
H2O2 proportionally reduced the intensity of absorption of
WONPs at 930 nm (Fig. 2a). Typically, the number of WONPs
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Fig. 2 Optimization of the composition. a UV–vis–NIR spectra of the WONPs suspension post the addition of different amounts of H2O2. The oxidation of
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WONPs that were partially (middle) to entirely oxidized (right). c The level of intracellular ROS measured using the H2DCFDA probe. For cancer cells, they
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For hepatocytes, they were incubated with either Mito(T)-pep-Nuc(T) or a mixture of Mito(T) and Nuc(T) under an identical condition. d The XPS spectra
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that can be conjugated to an individual MSN was measured
to be around 235, giving a total concentration of 2.4 × 1016
WONPs per mL solution. We next fixed the concentration of
WONPs, and adjusted the amount of Ce6 payload to the one
best fulfilling the requirements of the SOS depletion and
heating power abolishment. As calculated, those WONPs
(~4.5 nm in diameter) are expected to consume 1.5-fold more
oxygen species, that is, 5.3 μmol SOS. Under irradiation duration
(15 min, 1W cm−2), given a photon generation efficacy of 3.7 ×
10−3 cm2mW−1 s−1, a 63.0% quantum yield, and an extinction
coefficient as 3.5 × 10−3 (ref. 36), the optimal concentration
of Ce6 was calculated to be 1.7 mM. As such, we prepared
various platforms carrying different amounts of Ce6. Both the
SOS levels in Mito(T)-pep-Nuc(T) and control (Ce6 alone)
groups were measured post illumination. We further calculated
the extent of SOS consumption. We also recorded the
temperature profiles after the second-round irradiation (1064-
nm laser; Fig. 2b). Not surprisingly, a reduced WONPs
availability led to weakened heating power. Moreover, we noticed
that the optimal concentration of Ce6 herein was determined to
be 2.1 mM, slightly higher than the predicted value, presumably,
due to heterogeneous illumination payloads received that differed
from the condition used for theoretical calculation. The
UV–vis–NIR spectra of optimized samples before and after
633-nm laser irradiation were also recorded (Supplementary
Fig. 9). As expected, the absorption of WONPs in NIR region
decreased accordingly. Besides, we found the irradiation with
633-nm laser caused minor temperature elevation (<2.5 °C,
Supplementary Fig. 10), possibly owing to the ever-decreasing
optical absorption of WONPs. The release profiles of Ce6 with or
without Cathepsin B enzymes were also evaluated as shown in
Supplementary Fig. 11. With respect to the slow premature
release of Ce6, the participation of enzyme noticeably promoted
the liberation (~10.0% within 8 h). We believe that both the
electrostatic interaction between Ce6 and amine-functionalized
MSNs and the capping effect of WONPs help inhibit the
premature release.
Cellular uptake and distribution. Before moving to in vivo
analysis, we assessed the performance of our platform in vitro. As
shown in Fig. 2c, the intracellular levels of ROS in both HCT-116
(human primary colon cancer cell line) and HHL-5 (hepatocyte
cell line) were relatively low. Upon the laser irradiation, it sub-
stantially increased by 182-fold in HCT-116 cells that received
Mito(T)-pep-Nuc(T) (Supplementary Fig. 12), whereas hepato-
cytes were negligibly influenced. Once the activity of Cathepsin B
was inhibited, the ROS generation was attenuated in cancer cells.
Furthermore, the HHL-5 cells, when incubated with a mixture of
Mito(T) and Nuc(T), cannot be rescued as effectively as did by
Mito(T)-pep-Nuc(T) (Supplementary Fig. 12). One may argue
that it was the reduced internalization of Nuc(T) which was
behind the inadequate scavenging. We thus analyzed the content
of tungsten of cells incubated with either Mito(T)-pep-Nuc(T) or
Nuc(T) (2.4 × 1016 WONPs per mL; Supplementary Fig. 13). Less
uptake of Nuc(T) was noticed, accounting for 87.2% of that of
Mito(T)-pep-Nuc(T). As such, one can still expect the vast of
generated SOS to be depleted. The distance between Nuc(T) (in
the nucleus) and SOS (nearby mitochondria) might be part of the
reasons why the scavenging capacity of Nuc(T) was weakened.
Furthermore, we assessed the serum stability of Mito(T)-pep-Nuc
(T). Figure 2d shows the X-ray photoelectron spectra (XPS)
results of WONPs before and after incubation. Clearly, the
WONPs stayed intact as reflected by the almost constant W(V) to
W(VI) ratio, thus ruling out the possibility of WONPs under-
going premature oxidation.
Furthermore, the subcellular distribution of Mito(T)-pep-Nuc
(T) post endocytosis was analyzed. For Nuc(T), they were labeled
with Alexa Fluor-488 in order to make them distinguishable from
Ce6-loaded Mito(T). Figure 3a shows the fluorescence micro-
graphs of cells after the incubation with nanoparticles for 4 h. In
hepatocytes, the Ce6 fluorescence of Mito(T) overlapped with
that of Nuc(T), indicating no sign of structure rupture. By
contrast, in HCT-116 cells, the pattern of Mito(T) nanoparticles
differed considerably from that of Nuc(T). To precisely analyze
their distribution, mitochondria and nucleus were stained
individually post the incubation with Mito(T)(no payload)-pep-
Nuc(T)(dye-labeled) and Mito(T)(Ce6-loaded)-pep-Nuc(T)(no
label), respectively. We confirmed the accumulation of Mito(T)
and Nuc(T) in mitochondria and nucleus (Fig. 3b, c), respectively.
Furthermore, we have observed the time-dependent enrichment
of WONPs in the nucleus (Supplementary Fig. 14). Specifically,
diffusive distribution of the internalized WONPs after a 30-min
incubation indicated the escape of Nuc(T) from endolysosomes37.
The overlapping between Hoechst and Alexa Fluor-488 indicated
the nuclear entry of Nuc(T), which was accomplished within 90
min. When we inhibited the activities of several enzymes before
the incubation with Mito(T)-pep-Nuc(T)(dye-labeled), we found
that only the impaired Cathepsin B blocked nuclear-entry of Nuc
(T) (Fig. 3d). We also proved that the internalization of Mito(T)-
pep-Nuc(T) was Clathrin-dependent on the basis of fact that the
presence of Clathrin inhibitor, chlorpromazine (Fig. 3d)38,
noticeably decreased the endocytosis.
Morphology changes of mitochondria. An in situ observation
was conducted using fluorescence imaging equipped with a live
cell culture chamber. Figure 3e shows three representative cells,
whose fluorescence micrographs were recorded in parallel during
the laser irradiation. Based on these results, the populations of six
classes of mitochondria were analyzed and displayed on the right
panel of each group39,40. The population of each subtype as a
function of irradiation duration was summarized in a heat-map
(Fig. 3f). We found that the small globule-like mitochondrion was
least prone to PDT, whereas the branched tubule-like and twisted
counterparts exhibited the highest vulnerability. In Groups I and
II, the population of branched tubule-like mitochondria reduced
over time, in directly opposite to that of those twisted counter-
parts. The measured mean aspect ratio of mitochondria also saw a
decrease over time in all three groups (Supplementary Fig. 15). It
coincided with the increasing population of the small globule,
whose aspect ratio was the smallest among all39. Considering the
heterogeneity of mitochondria, our results suggested that subtype
greater in length might be more vulnerable to PDT than its
shorter counterparts do.
Activities of OXPHOS and GLY. We used the Seahorse XF
Extracellular Flux analyzer to record the values of oxygen con-
sumption rate (OCR) and the extracellular acidification rate
(ECAR)40. Figure 4a illustrates a typical metabolic process that
the glucose could undergo in cancer cells. First, the glucose is
catabolized to pyruvate, an intermediate fueling both OXPHOS
and GLY26. During OXPHOS, the pyruvate enters the tri-
carboxylic acid (TCA) cycle along with oxygen, thereby makes it
feasible to monitor the activity of OXPHOS by measuring the
OCR40. Alternatively, the pyruvate can be engineered into lactate
(in GLY), the exocytosis of which acidified the extracellular milieu
as measured by the changes in ECAR40. Here, platforms differed
in their organelle selectivity were eveluated (Fig. 4b and Supple-
mentary Fig. 16). Analyses of both OCR and ECAR can be
divided into three stages involved in the step-wise introduction of
chemical effectors (Fig. 4a). During OXPHOS, the OCR at the
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basal level is measured before the ATP synthase (Complex V)
is inhibited by Oligomycin40. Next, the mitochondrial membrane
is permeabilized with FCCP (carbonyl cyanide-4 (tri-
fluoromethoxy) phenylhydrazone), constantly maximizing the
OCR due to unregulated electron flow40. Both the upper limit of
OXPHOS and the spare respiratory capacity can be measured
simultaneously. Afterward, a mixture of rotenone and antimycin
A was introduced that respectively inhibit the functions of
Complex I and III40, collectively blocking OXPHOS. For the
ECAR measurement, glucose, Oligomycin, and 2-DG (2-deoxy-
glucose) are sequentially added during steps I–III, in order to
provide substrates for GLY, inhibit the Complex V, and abrogate
OXP
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Fig. 4 GLY and OXPHOS activities of treated cells. a A schematic illustrating how GLY and OXPHOS are executed, along with the network showing the
essential species involved in these two processes. The chemical effectors involved during the measurement of OCR and ECAR are shown at the bottom.
Red and blue arrows stand for the up- and down-regulation of metabolic activities, respectively. b Profiles of OCR and ECAR measured by a Seahorse XF-
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shown in b. The captions shown on the right are valid for both b and c. A color bar on the right indicates the color scales. d Bioluminescence micrographs of
luciferase-transfected HCT-116 cells that were incubated with different types of platforms before laser irradiation. D-Luciferin was added into the culture
medium of cells right after the laser irradiation to show the availability of ATP. e Radiance intensity of cells shown in d. The “T” and “N” were used to
demonstrate the presence and absence of targeting moieties toward either nucleus or mitochondrion, respectively. For the Mito(T)-Nuc(T), it represented
the platform composed of nuclear-targeting WONPs (Nuc(T)) and mitochondrion-targeting MSNs (Mito(T)) that was covalently linked to each other via a
linker that was non-cleavable by Cathepsin B. P values were calculated by one-way ANOVA (***p < 0.001, **p < 0.005)
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GLY through competitive binding with glucose hexokinase40, the
upper-stream enzyme of the glycolytic pathway. Specifically, as
shown in Fig. 4b, it was found that the treatments mediated by all
these five platforms, including the Mito(T)-pep-Nuc(T), Mito(T)-
pep-Nuc(N), Mito(N)-pep-Nuc(T), Mito(N)-pep-Nuc(N), and
Mito(T)-Nuc(T), possess negligible threat to hepatocytes as
reflected by their OXPHOS activities. The calculated values of
basal respiration rate, ATP production, and the maximal
respiration capacity, as displayed in a heat-map (Fig. 4c) sup-
ported this assertion. Likewise, the ECAR profiles of hepatocytes
indicated GLY activity was also minorly influenced (Fig. 4b, c).
Our previous findings suggested that platforms of this kind could
keep intact after its internalization into cells. As such, the
expected reaction between SOS and WONPs as well as the loss of
heating power of the latter one can take place at wherever the
whole platform accumulated. Conversely, individual components
like Mito(T/N) and Nuc(T/N) were not suitable for future tests
owing to their negative influence on either OCR (Supplementary
Fig. 16) or ECAR (Supplementary Fig. 17) of hepatocytes. Due to
the safety concern, only the five hybrid platforms were discussed
and exploited further.
In cancer cells, these platforms affected metabolic activities
differently. The treatment mediated by Mito(T)-pep-Nuc(T)
resulted in the strongest inhibition in activities of both OXPHOS
and GLY, whereas Mito(T)-pep-Nuc(N) and Mito(N)-pep-Nuc
(T) only shut down the energy produced through OXPHOS and
GLY, respectively. Of note, the OCR activity of cells received Mito
(N)-pep-Nuc(T) was increased to a level higher than that for
normal cancer cells, revealing that OXPHOS could compensate
the energy loss due to GLY blockage, coinciding that described in
literature26. Although the safety of both Mito(N)-pep-Nuc(N)
and Mito(T)-Nuc(T) was assured, their therapeutic performances
in vitro were unsatisfactory; the activity of neither type of
metabolism experienced a notable reduction, making the in vivo
exploration of less value. Using the luciferase-based assay, we also
quantified the level of intracellular ATP. Figure 4d shows the
bioluminescence graphs of cells received different treatments. It is
found that the ATP in cells treated with Mito(T)-pep-Nuc(T) was
reduced to a level below the detection limit of bioluminescence
imaging (BLI) modality (Fig. 4e), whereas the Mito(T)-Nuc(T)
led to the minimal reduction. Besides, the ATP level in cancer
cells treated with Mito(T)-pep-Nuc(N) was higher than that of
Mito(N)-pep-Nuc(T) group (Fig. 4e), suggesting a stronger
capacity of GLY in compensating the energy loss relative to
OXPHOS. Possibly, it can be explained by the faster action of
GLY relative to OXPHOS.
Pharmacokinetic and apoptotic profiles. The green fluorescence
protein (GFP)/luciferase-transfected HCT-116 cells (HCT-
116GFP/Luc) were used for establishing DLM animal model. Next,
we evaluated the bio-distribution profiles of Mito(T)-pep-Nuc(T).
Figure 5a shows the number of nanoparticles in different tissues
as a function of time. Maximal accumulation of Mito(T)-pep-Nuc
(T) in the liver was witnessed at 8 h (68.8% of the total injection),
followed by slow clearance. The blood circulation profile was also
assessed, with the half-life of nanoparticle estimated to be 1.24 h.
Here, the declined blood availability agreed well with the quick
entry of nanoparticles into the reticuloendothelial system (liver
and spleen). Such a manner effectively helps reduce the duration
of time necessitated for injected nanoparticles to enrich in the
liver to a noticeable extent.
We next managed to understand the distribution profiles of
Mito(T)-pep-Nuc(T) at the cell level. Specifically, mice bearing
primary hepatocellular carcinoma (HCC) or DLM were
involved. In both models, they received a tail vein injection of
Mito(T)-pep-Nuc(T), with an interval of 8 h allowed for these
injected nanoparticles to accumulate in the liver. Figure 5b, c
shows the necropsy images of liver tissues collected from HCC-
and DLM-bearing mice, respectively. They were then processed
into single-cell suspension, with both cancer and Kupffer cells
sorted according to the expression of GFP and F4/80, respectively.
Intracellular Ce6 fluorescence was recorded using flow-cytometry
(Fig. 5d, e for HCC and DLM, respectively), with the changes in
intensity calculated by normalizing the measured value to that of
control cells received no treatments (Fig. 5f, g for HCC and DLM,
respectively). The distribution of nanoparticles in the presence of
HCC meets our expectation, wherein the enrichments in Kupffer
cells outnumbered that in cancerous counterparts. This can be, at
least partially, explained by the lack of deep tumour penetration
capacity of nanoparticles against the high interstitial pressure. By
contrast, the much smaller volumes of metastasis nodule (around
1/10–1/5 size of the primary tumour) as observed in DLM allows
cancer cells to compete more strongly with Kupffer cells for
nanoparticles. This was supported by the observation that
accumulation of nanoparticles in Kupffer cells was only slightly
higher than in cancer cells (Fig. 5g).
Furthermore, we assessed the therapeutic potential of Mito(T)-
pep-Nuc(T). Sorafenib, the first-line therapeutic for liver
cancer41, was also included. All mice other than those in
sorafenib and control groups received laser treatment at 24 h
post the administration of therapeutics. We confirmed that the
exposure to 633-nm laser was safe in our case. Supplementary
Figure 18 shows the changes in three biomarkers, including
alanine aminotransferase (ALT), total protein (TP), and total
bilirubin (TBIL). The expression levels of TP and TBIL varied
shortly after laser exposure and recovered within 2 weeks. This
reveals that the stress condition induced by illumination was
temporal and overall tolerable.
We next conducted sequential laser irradiation. Figure 6a
shows the representative immunofluorescence micrographs of
liver tissues with active Caspase 3, a biomarker of apoptosis42.
The metastasis lesions can be readily recognized based on their
GFP expression. Massive cell death in metastasis was witnessed in
mice received treatments mediated by either Mito(T)-pep-Nuc(T)
or Mito(T)-pep-Nuc(N), but not Mito(N)-pep-Nuc(T), indicating
that the cell death here was associated with the mitochondrial
apoptotic pathway. All the tested therapeutics delivered the
promise of safety as reflected by the negligible death in
hepatocytes. For comparison, we also analyzed the apoptosis
profiles of liver tissues from host received treatment mediated by
non-cleavable, Mito(T)-Nuc(T). Negligible cell death was wit-
nessed in both cancer cells and hepatocytes (Supplementary
Fig. 19). This finding implies that the non-cleavable platform only
affects the cells minimally, independent of their types. As such, its
therapeutic outcome, if any, is expected to be not much better
than that of phosphate-buffered saline (PBS), making us exclude
the non-cleavable platform from further assessment. The cell
death induced by different therapeutics was further validated
quantitatively via flow-cytometry. In this case, the expression of
cleaved PARP, a biomarker indicative of end-stage apoptosis43,
was evaluated. Those cancer cells were sorted according to their
GFP expression, followed by the permeabilization and intracel-
lular staining. As shown in Fig. 6b–d, significant cell death was
noticed in the Mito(T)-pep-Nuc(T) group, which outperformed
that of Mito(T)-pep-Nuc(N).
Changes in gene expression. We assessed the global changes in
gene expression (Fig. 7). A map of total 5542 recognized genes
was shown in Fig. 7a, and Gene Ontology (GO) analysis was
conducted. Here, we focused only on engineered materials. It can
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be seen that more GO annotations were enriched for up-regulated
genes (Fig. 7b) than down-regulated (Fig. 7c) ones, with top-10
annotations displayed in Fig. 7d, e, respectively.
Next, we analyzed the GO analysis results term-by-term. For
biological process, both the up- and down-regulated genes in the
Mito(T)-pep-Nuc(T) group were associated tightly with stress
response (Supplementary Fig. 20a), whose significance was higher
than that of the other two groups (Supplementary Figs. 21a and
22a). Meanwhile, the induction of apoptotic processes was
uniquely found in the Mito(T)-pep-Nuc(T) group. As a matter
of fact, the stress responses could take place long before apoptosis
becomes necessary. Once the damage is beyond the cell’s capacity
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to repair, self-destruction could be iniated44. A closer association
of several down-regulated genes with metabolic process manip-
ulation in the Mito(T)-pep-Nuc(T) group (Supplementary
Fig. 20b) than the other two (Supplementary Figs. 21b and 22b)
validated the effectiveness of dual-targeting against a tumour.
Also, the influence of Mito(T)-pep-Nuc(T) reached to several
organelles (Supplementary Fig. 23a) to an extent more significant
than it did by the other two (Supplementary Figs. 24a and 25a).
We confirmed the association of down-regulated genes with cell-
to-cell adhesion occurred during metastasis45 when both
organelles were impaired (Supplementary Figs. 23b, 24b and
25b). To become metastatic, the subunits of microfilaments
supporting the cancer cells undergo intense, ATP-dependent
disassemble-assemble cycles46. Thereby, it is not hard to under-
stand the depletion of ATP led to the loss of cell-to-cell adhesion
(Supplementary Fig. 26). No similar implication was found in
groups of Mito(T)-pep-Nuc(N) (Supplementary Fig. 27) and
Mito(N)-pep-Nuc(T) (Supplementary Fig. 28), again revealing
their limitations in globally influencing the cellular homeostasis.
The KEGG enrichment revealed that Mito(T)-pep-Nuc(T)
treatment interfered the protein engineering executed in the
endoplasmic reticulum (ER), way stronger than that for DNA
replication retardment caused by Nuc(T)-mediated intra-nuclear
PTT (Supplementary Fig. 29a). Previous reports suggest that the
execution of PDT or PTT might lead to the lethal accumulation of
misfolded proteins in ER, referred to as unfolded protein
response (UPR)47. Presumably, a particular population of those
down-regulated genes (Supplementary Fig. 29b) might critically
be linked to the elimination of misfolded proteins. A similar
enrichment was witnessed in the up-regulated genes of the Mito
(T)-pep-Nuc(N) group (Supplementary Fig. 30) but not in the
Mito(N)-pep-Nuc(T) group (Supplementary Fig. 31), indicating
that action of UPR relies more on the fueling of GLY than
OXPHOS.
Proteome study. Cellular compartments of these sorted cancer
cells were labeled with tandem mass tag (TMT) before the ana-
lysis with mass spectra. Among the numerous recognized pro-
teins, we focused on proteins clustered around mitochondrion,
nucleus, and ER. Figure 8a shows the protein–organelle interac-
tion networks. Down-regulation of ribosomal proteins, ER cha-
perone, and heat-shock protein (HSPA5) were confirmed.
Furthermore, we found that mitochondria and nucleus were
differently affected. In detail, the mitochondrial ATP production
machinery was most vulnerable to treatment. In the nucleus, the
results indicated that the activity of cell replication changed most
considerably due to the depletion of pyrimidine, an essential
substrate of nucleotide production48. Second and third to this
were the functions of the ribosome and ubiquitination, respec-
tively, whose abrogation promoted UPR.
Mito(T)-pep-Nuc(T)
Mito(T)-pep-Nuc(N)
Mito(N)-pep-Nuc(T)
Sorafenib
Control
0 102 103 104 105
0 104103102–102
200
175
150
75
50
25
0
Parenchyma Metastasis
Metastasis
Parenchyma
Caspase 3
GFP
GFP + caspase 3
Mito(T)-pep-Nuc(T)
Sorafenib
b
c
d
a Mito(T)-pep-Nuc(N)
Mito(N)-pep-Nuc(T)
Fluorescence intensity (a.u.)
Ch
an
ge
 in
 in
te
ns
ity
N
or
m
al
iz
ed
 c
ou
nt
s
N
or
m
al
iz
ed
 c
ou
nt
s
Fig. 6 Apoptosis profiles of liver metastatic lesion and parenchyma. a Immunofluorescence micrographs showing the expression of active Caspase 3
(labeled in red) in both metastasis (GFP positive, green) and pan-cancer, normal parenchyma (GFP negative). Scale bars: 80 μm (left) and 20 μm (right).
b, c Flow-cytometry results showing the intracellular cleaved-PARP expression. The freshly harvested liver tissues from mice received different treatments
were digested and sorted using flow-cytometry on the basis of the expression of the GFP protein, sequentially followed by fixation, permeabilization, and
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Next, we analyzed these proteins that were functionally
associated with biological processes including ER stress, GLY,
ATP productions, and intrinsic apoptosis. Owing to the blocked
DNA replication, an arrested cell cycle was expected, which was
also evaluated here. A heat map was generated on this basis
showing the changes of all related proteins (Fig. 8b), along with a
scheme illustrating the anticipated pathways (Fig. 8c). It was
found that both the ER stress and the release of cytochrome C can
prime the cleavage of pro-Caspase 3 and eventually led to cell
death. Notably, the AMPK (AMP-activated protein kinase)
protein was inactivated in this case. Typically, the AMPK
pathway could activate when facing the loss of ATP49. We found
the up-regulation of liver kinase B1, an inhibitor of AMPK49,
might rationalize the inactivation of AMPK. Besides, the silent
AMPK allowed the production of fatty acid, through which the
ATP was consumed further. Likewise, the up-regulated genes that
positively associated with the lipid biogenesis also helped deplete
the ATP storage.
Attenuation of DLM in vivo. Figure 9a shows the schedule of
therapy; ten days were allowed for the onset of DLM, with a clear
sign of metastasis nodule(s) formation in liver monitored by BLI
(Fig. 9b, c). For the mice received PBS (control), the progress of
metastasis was quick, which occupied the whole liver in 23 days.
Expectedly, mice treated with Mito(T)-pep-Nuc(T) eliminated
the metastasis lesions considerably (Fig. 9c). This also indicates
that a vast majority of metastasis lesions are accessible to Mito
(T)-pep-Nuc(T). Meanwhile, Mito(T)-pep-Nuc(N) or Mito(N)-
pep-Nuc(T), though sort of effective at the very beginning, saw
local relapse at rates even higher than that of control (Fig. 9b, c).
We also noticed that sorafenib exerted a better therapeutic effect
than either one of the half-targeting platforms (Fig. 9c), albeit
long-term protection was not reached.
The mice were sacrificed for tissue collection and stained with
hematoxylin and eosin (H&E). Figure 9d shows the representative
micrographs of an individual lobe (for a full spectrum of them,
please refer to Supplementary Figs. 32–36). Micronodules and
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Fig. 7 Changes in gene expression. a A heat map showing the expression levels of 5542 identified genes in liver metastasis lesions of mice received
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local vessel invasion events were recorded (Fig. 9e) and quantified
(Fig. 9f–h). In the Mito(T)-pep-Nuc(T) group, metastasis lesion
decreased in number and volume, thus favoring an improved
prognosis (median survival: 55 days versus 19 and 29 days for
control and sorafenib groups, respectively, Fig. 9i). By contrast,
Mito(N)-pep-Nuc(T) promoted the generation of more metas-
tasis nodules (Fig. 9f), wherein a poor prognosis was witnessed
(Fig. 9i).
Assessments of compatibility. The safety concern of our plat-
form was addressed in different aspects. First, we assessed the
inflammatory reaction. The mice carrying DLM were treated
prior to sacrifice on Days 3 and 15 as described in the schedule
(Fig. 9a), followed by the extraction of the hepatic fluid. Then, the
expression level of a variety of cytokines was measured as shown
in the heat map (Fig. 10a). Only weak inflammation, as marked
by the increased expression of G-CSF, I-309, IL-13, and PDGF-
BB, took place in the Mito(T)-pep-Nuc(T) group (Day 3, I). The
inflammation was temporal and weakened within the following
days (Day 15, II). Likewise, treatment mediated by Mito(T)-pep-
Nuc(N) (Fig. 10a), but not Mito(N)-pep-Nuc(T), also resulted in
hepatic inflammation, which recovered transiently. Up-regulation
of an overwhelming portion of the tested cytokines revealed that
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Fig. 9 In vivo anti-metastasis effect. a A schematic showing the procedures of in vivo experiments (n= 7 in each group). b Bioluminescence graphs of mice
at different time points after receiving the treatments with the radiance of liver tissues quantified and shown in c (n= 3). In the box plot, the upper and
lower quartile as outlined by top and bottom boundary were divided by line showing the median value. d Necropsy of representative liver tissues collected
at day 30 or the day they died if earlier than day 30. (A full spectrum of necropsy is shown in Supplementary Figs. 26–30). e Representative micrographs
with H&E staining showing the pathological features of liver metastasis and pan-cancer normal parenchyma. The micrographs on the right panel show the
details of regions that have been highlighted with either the green circle or blue box at a higher magnification. f Number of nodules that existed in an
observation area (×10, average of ten fields for each mouse). g Area of the liver tissue that was occupied by metastasis. h The number of cases of invasion
into liver vessels (n= 3). Median value was shown as line in the middle of the plot. i Survival profiles of mice received different treatments during an
observation period of 80 days (n= 7). Data are presented as mean ± s.e.m. P values were calculated by one-way ANOVA (***p < 0.005, *p < 0.05)
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the Mito(N)-pep-Nuc(T) remodeled the niche toward one
favoring the cancer progress. It is thereby easy to understand the
suboptimal prognosis in the case of Mito(N)-pep-Nuc(T).
Next, we assessed the changes in systematic immunity caused
by treatment mediated by Mito(T)-pep-Nuc(T). To this end,
flow-cytometry was leveraged to measure the populations of
CD3+ T cells50. Specifically, the population of CD4+ T cells
increased from 28.3% (control) to 46.3% at Day 1 (Fig. 10b, c)
and gradually declined to 26.6% on Day 7. The mitigated
inflammation was also reflected by the changes in CD8+ T cell
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Fig. 10 Long-term safety profile. a A heat-map showing the changes in the expression of a spectrum of inflammatory cytokines in the liver tissue (n= 3 at
each time point). Their levels of expression were first analyzed using a protein antibody array, normalized to that of the normal control, and shown in a fold-
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populations (Fig. 10c). Altogether, the evidence is enough to
support the assumption that the host is well tolerable with the
temporal inflammatory response induced by therapy.
Furthermore, we confirmed that prolonged exposure to Mito
(T)-pep-Nuc(T) led to negligible complications (Fig. 10d). The
promise of safety was also assessed by hematology results
(Fig. 10e). Functions of the liver were minorly affected during
the early exposure (Day 1). Stress was induced and relieved
gradually thereafter. Besides, we found that either the spleen or
kidney was vulnerable to the treatment, which can be explained
by the limited accumulation of nanoparticles in these organs as
verified by the pharmacokinetic study.
Discussion
The concept of targeted delivery at precision down to organelle
level has emerged for a while51–53, the action, however, is detri-
mental to both cancerous and healthy cells in most cases. As such,
delivery strategies harnessing targeting moieties are favorably
used in the hope of making lesions the only site for the drug to
accumulate. To effectively treat DLM while sparing abundant
normal cells, alternative methods beyond active targeting delivery
should be employed. Attempts have already been made with a
similar aim to confine the action in cancer cells by harnessing the
ubiquitous pathologic features tumour develops54,55. So far,
success in DLM model remains elusive, in which the platform
should be reconfigured by taking a full consideration of the
sophisticated liver niche. We demonstrated that the concurrent
interruption of GLY and OXPHOS activities in cancer cells could
effectively eliminate liver metastasis while sparing hepatocytes.
WONPs play dual roles as both SOS-scavenger and PTT agent.
Once optimized, the SOS produced during PDT could be stoi-
chiometrically depleted by WONPs, and in turn, be oxidized
entirely into PTT-inert species. Such a feature meets our expec-
tation of reaching a termination between PDT and PTT. Another
crucial parameter is the choice of the enzyme for cleaving the
Mito(T)-pep-Nuc(T). Given the aberrantly high expression of
Cathepsin B in cancer cells, the peptide cleavable by this enzyme
was selected to link Nuc(T) and Mito(T).
In summary, a metabolism-based, tumour-selective therapeutic
strategy was demonstrated here to conquer liver metastasis by
harnessing an energy depletion mechanism. Their interaction
with cellular components and influences on the metabolic man-
ners of cells have been studied. Further proof-of-concept results,
including the profiles of survival and inflammatory response,
confirmed the effectiveness and compatibility of our strategy.
Given the abnormal expression of Cathepsin B enzyme in a
spectrum of tumours, as well as the ubiquitous metabolic phe-
notype of cancer cells, the strategy demonstrated here could have
implications in cancers of various types.
Methods
Materials. Tungsten hexachloride (WCl6, ≥99.9%), (4-carboxybutyl)triphenyl-
phosphonium bromide (TPP, 98.0%) (3-aminopropyl)triethoxysilane (APTES,
≥99.0%), poly(acrylic acid) (PAA, MW~2 kDa), diethylene glycol (DEG, ≥99.0%),
ethylenediamine (EDA), cysteamine (≥95.0%), N-(3-dimethylaminopropyl)-N
′-ethylcarbodiimide hydrochloride (EDC, Bioxtra), N-hydroxy-succinamide (NHS,
98.0%), and chlorpromazine (≥98.0%) were all obtained from Sigma-Aldrich
(United States). Tetraethyl orthosilicate (TEOS), hexadecyl trimethyl ammonium
bromide (CTAB), hydrogen peroxide (H2O2), and ethanol were all purchased from
J&K Scientific (P. R. China) that were all of the analytic grades and used without
further purification. Chlorin e6 (Ce6,≥99.0%) was purchased from Cayman Che-
mical (United States). The Cathepsin B-cleavable peptide (NHS-Gly-Phe-Lys-Phe-
Lys-Gly-maleimide, ≥97.0%) and nuclear localizing sequence (NLS,
CGGGPKKKRKVGG-maleimide, ≥99.0%) were synthesized by Yarebio (P. R.
China). Recombinant proteins of Caspase 3, MMP-2, and Cathepsin B protein were
all purchased from R&D Systems (United States). The inhibitors of Caspase 3,
MMP-2, and Cathepsin B, Ac-DEVD-CHO, SB-3CT, and CA-074 methyl ester,
respectively, and sorafenib (≥99.9%) were obtained from Selleckchem (United
States). Modified McCoy’s 5a medium was obtained from American Type Culture
Collection (ATCC, United States). Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), PBS, penicillin/streptomycin, and H2DCFDA probe were
obtained from Invitrogen (Thermo Fisher Scientific, United States). D-Luciferin
potassium salt (≥95.0%) was purchased from Sciencelight (P. R. China). Deionized
(DI) water produced with a Millipore ultrapure water system (United States)
featuring a resistivity of 18.2 MΩ cm and was used throughout the experiments.
Cell lines. The HCT-116, a human primary colon cancer cell line, was purchased
from ATCC (CCL-247). Human immortalized hepatocytes, HHL-5, were obtained
from Culture Collection of the Chinese Academy of Sciences (Shanghai, P. R.
China). HCT-116 cells were cultured and maintained in modified McCoy’s 5a
medium supplemented with 10% FBS and 1% penicillin/streptomycin. HHL-5 cells
were cultured under an identical condition except for the culture medium that was
replaced by DMEM. Cell cultures were maintained in an incubator at 37 °C in a
humidified atmosphere with 5% CO2. The medium was replaced every other day
until the confluency of cells was in the range of 80–90%. For the in vivo and part of
the in vitro analyses, the HCT-116GFP/Luc cells were used. They were established
through transfection with lentivirus vectors carrying the plasmids of both firefly
luciferase and GFP. The obtained HCT-116GFP/Luc cells were cultured in modified
McCoy’s 5a medium supplemented with 20% FBS and 1% penicillin/streptomycin.
Likewise, human HCCcells, HCC-LM3 (obtained from Shanghai Zhongshan
Hospital), were transfected to express GFP, giving the HCC-LM3GFP cells. They
were cultured in DMEM supplemented with 20% FBS, 1% penicillin/streptomycin,
and 1% (vol/vol) mycoplasma inhibitor (Biological Industries, Israel). The mouse
monocyte, RAW 264.7 cells (obtained from ATCC), were cultured in DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin.
Mouse model of liver cancer. Female BALB/c nu/nu nude mice (4–6 weeks old)
were purchased from the Comparative Medicine Centre of Yangzhou University
and raised in a specific pathogen-free (SPF) facility. The liver metastasis was
established based on a published protocol with minor modifications. In brief, HCT-
116 cells were allowed to grow in a 75-cm3 plate until a 90% confluency was
achieved before their digestion and resuspension in the serum-free culture med-
ium. Afterward, the spleen of the mouse was exposed under sterilized condition
through the incision on its left flank, followed by the titration of 1 × 106 cells
suspended in 50 μL of medium. The splenectomy was conducted at 2 min later. In
order to establish the HCC animal model, the left lobe of the nude mouse was
exposed surgically, with a total of 2 × 106 HCC-LM3GFP cells administrated within
30 s. Afterward, a cotton bud was pressed gently on the injection site before the
needle was retracted, and kept still for another 2 min in order to stop the bleeding.
In order to eradicate the liver metastasis, different therapeutics were
leveraged. For the synthesized hybrid nanomedicine, including Mito(T)-pep-
Nuc(T), Mito(T)-pep-Nuc(N), and Mito(N)-pep-Nuc(T), their compositions
were optimized as described in the text, and suspended in PBS prior to their
systematic administration into mice carrying liver metastasis (dosage: 15 mg per
mouse) at Day 10 post the inoculation of HCT-116GFP/Luc cells (15 mg per
mouse, n= 7 in each group). After 24 h, an incision (5 cm in length) in parallel
to the longitudinal direction of the liver was made to expose the whole tissue
under the sterilized condition, followed by the laser irradiation. In a typical cycle
of treatment, the power densities of PDT and PTT were kept at 1, and 0.75 W/
cm2 for a duration of 15 and 10 min, respectively, and the irradiation of the
whole liver tissue can be finished with three cycles of subsequent irradiation.
During this process, the mice were all kept anesthetized using inhalation
anesthesia by isoflurane. For sorafenib, no laser irradiation was executed after
the systematic injection of therapeutics suspended in PBS (dose regimen: 25 mg
kg−1 weight, n= 7). This was repeated every 4 days (as illustrated in Fig. 8a on
Day 1 and Day 5).
All the protocols for the animal tests have been reviewed and approved by the
Committee on Animals at Nanjing University and performed in accordance with
the guidelines provided by the National Institute of Animal Care.
Synthesis. Briefly, the W18O49 nanoparticles encased by PAA were prepared using
a polyol method by taking WCl6 and DEG as the metal precursor and the reducing
agent in addition to its role as the solvent, respectively34. Their thiolation was
realized through the conjugation of cysteamine with PAA-functionalized W18O49
nanoparticles via EDC/NHS. The as-prepared, thiol-terminated W18O49 nano-
particles were covalently conjugated with NLS peptide. In a typical experiment, 15
mg of the synthesized NLS peptide was dissolved in 2 mL PBS containing thiol-
functionalized W18O49 nanoparticles (1 × 1018 particles per mL), and the covalent
binding between the thiol group and maleimide was allowed to proceed at 4 °C
overnight that was protected from direct light exposure. Afterward, the NLS-
functionalized W18O49 nanoparticles, denoted by Nuc(T), was suspended in PBS to
a final concentration of 2 × 1017 particles per mL. For the Mito(T), it was prepared
at room temperature by harnessing the EDC/NHS chemistry. Typically, MSNs
were firstly modified with APTES by following a published method33, and TPP
(13.2 mg) was dissolved in 5 mL ethanol suspension of APTES-functionalized
MSNs (1 × 1017 particles), along with 10 μL of EDA to facilitate the coupling
between the carboxyl group of TPP and amine of APTES. After a 4 h reaction
under an ambient condition, the TPP-functionalized MSNs were harvested via
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centrifugation and were purified through repeated washing with DI water. Next,
different amounts of photosensitizer, Ce6, were loaded into the interior of MSNs
through covalent binding with APTES as reported56. The Ce6-loaded Mito(T) were
collected and washed as mentioned above, before re-suspending in PBS to a final
concentration of 5 × 1015 particles per mL. The Cathepsin B-cleavable peptide (30
mg) was conjugated to the synthesized Mito(T) through the coupling between NHS
and the excess amine groups of Mito(T), followed by their conjugation with Nuc
(T) in a fashion similar to what was used for the functionalization of W18O49
nanoparticles with NLS peptide.
Fluorescent labeling of Nuc(T) was conducted, if necessary, prior to their
coupling with enzyme-cleavable peptide by following our published protocol with
slight modification34. Specifically, Alexa Fluor-488-maleimide (Thermo Fisher
Scientific, 0.5 mg mL−1 in PBS) was used to label Nuc(T) (5 × 1017 particles per
mL) according to the manufacturer’s instructions. The dye-labeled Nuc(T)
nanoparticles were purified via centrifugation and repeatedly washed with PBS to
remove non-specifically absorbed dyes.
Characterization. The morphology of nanoparticles was investigated by TEM
(TEM-200CX, JEOL, Japan) and HRTEM (TEM-2100, JEOL) The UV–vis–NIR
spectra of nanoparticles were recorded on a UV-vis spectrophotometer (UV3100,
Shimadzu, Japan). The Zeta-potential, as well as the DLS profiles of corresponding
nanoparticles, was measured at room temperature using a Zeta-sizer (Nano ZS,
Malvern, United Kingdom). Surface element composition was investigated by XPS
(K-Alfa, Thermo Fisher Scientific, United States) with a focused monochromatic Al
X-ray (1486.6 eV) source. The concentration of tungsten in each sample was
determined by ICP-MS (Agilent 7500ce, Agilent, United States).
Flow-cytometry analysis. For the evaluation of the intracellular expression level of
ROS, both HCT-116 and HHL-5 cells were seeded in a six-well plate and cultured
until a confluence of 80% was reached. Next, the culture medium was replaced by a
fresh one containing Mito(T)-pep-Nuc(T) (Ce6: 2.13 mM; Nuc(T): 2.35 × 1015
particles per mL). The incubation was allowed to proceed for 4 h under the con-
dition generally used for cell culture, followed by three washes with warm PBS to
remove excess nanoparticles. Next, the cells received sequential laser irradiations
((i) 633 nm at a power density of 1W cm−2 for 15 min; (ii) 1064 nm at a power
density of 0.75W cm−2 for 10 min). The intracellular level of ROS was evaluated
using a ROS-responsive probe, H2DCFDA (500 μL, 1 mM). After 10 min, the ROS-
associated fluorescence intensity was analyzed using flow-cytometry (FACS verse;
BD Bioscience, United States), and the data were processed using FlowJo software
(version 10.0.7).
For the quantification of apoptosis profiles of cancer cells metastasized to liver,
mice in different groups were sacrificed at 6 h post the second-round laser
irradiation (for sorafenib, the time point was extended to 12 h post its systematic
administration), with their liver tissues collected and minced into pieces with a
mean volume of 5 mm3 using an eye scissors. These tissue fragments were
immediately transferred to DMEM culture medium supplemented with 30 μg of
type IV collagenase (Sigma-Aldrich) and type I DNase (Roche) and incubated for
2 h at 37 °C. After the tissue fragments were softened, they were subjected to
mincing with a 400-mesh screen to acquire a suspension of single cells differ in
type. After the centrifugation (200g for 5 min), the cell debris in the supernatant
was discarded, leaving only the intact cells collected and resuspended in PBS. For
the cancer cells in the mixture, they were sorted by flow-cytometry on the basis of
their expression of GFP. The as-obtained metastatic cancer cells typically have
purities in the range of 88–95% and were used directly for down-stream assays if
necessary. Otherwise, they were cryopreserved using a freezing container at −80 °C
(Nalgene, United States).
For the quantification of nanoparticles accumulated in cancer and Kupffer cells,
mice bearing either HCC or DLM were injected intravenously with Mito(T)-pep-
Nuc(T) (dosage: 15 mg per mouse), followed by sacrifice at different time points to
harvest a serial of organs including liver, spleen, lungs, kidneys, in addition to
blood sample. The contents of tungsten were measured using ICP-MS. To assess
the accumulation difference between cancer and Kupffer cells, the liver tissues
collected at 8 h post the injection were processed into single-cell suspension, with
cancer and Kupffer cells sorted according to their expression of GFP and F4/80
(labeled 1h prior to the sorting using antibodies, clone: BM8, dilution: 1:100;
Invitrogen). Changes in the Ce6 expression level in those sorted cells were analyzed
and calculated by normalizing the measured values to that of HCC-LM3 and RAW
264.7 cells received no treatment for cancer and Kupffer groups, respectively.
For the analysis of population of different classes of CD3+ T cells in peripheral
blood of mice received the treatment mediated by Mito(T)-pep-Nuc(T), 100 μL of
whole blood were extracted and treated with ACK Lysis Buffer (BD Biosciences)
followed by surface staining with FITC-labeled rat-anti-mouse CD8a (clone: 53-6.7,
dilution: 1:50) and PE-labeled rat-anti-mouse CD4 antibodies (clone: RM4-5,
dilution: 1:20). The FITC-labeled rat IgG2a and PE-labeled rat IgG2a were selected
as isotypes (dilution: 1:50). All these antibodies were purchased from BD
Biosciences and used according to the manufacturer’s instructions.
Measurements of OCR and ECAR. The cells, both normal and cancerous, were
seeded in a special 24-well plate suitable for the Seahorse XF-24 Extracellular Flux
Analyzer (Agilent Technologies) at a density roughly the same as the one achieved
by using a traditional 24-well culture plate. Afterward, the cells were incubated with
different nanoparticles and sequentially treated as described above for Mito(T)-
pep-Nuc(T). The status of both OXPHOS and GLY have been evaluated at 1 h post
the second-round laser irradiation, with the chemical efforts sequentially intro-
duced as detailed in both Fig. 4a and a previous publication40.
Fluorescence imaging. In order to assess the subcellular distribution of Mito(T)-
pep-Nuc(T) after their uptake by cells (the protocol was the same as the one used
for the evaluation of the ROS level in cells using flow-cytometry), the structure of
mitochondria or nucleus was stained with MitoTracker Green or Hoechst 33342
(Thermo Fisher Scientific), respectively, for 10 and 5 min under an ambient con-
dition free from direct light irradiation. The fluorescence micrographs were col-
lected on a fluorescence microscope (BX51, Olympus, Japan) and processed using a
Bitplane Imaris software (version 7.4.2). For the time-lapse study, the fluorescence
microscope was equipped with a live cell imaging chamber that was coupled with a
gas controller (ibidi, Germany). In this case, the cells were placed in the envir-
onment containing 5% CO2 with the temperature set at 37 °C throughout the
imaging. To understand how the enzymatic activities of Caspase 3, MMP-2, and
Cathepsin B, as well as the presence of Clathrin influence the subcellular dis-
tribution of Nuc(T), they were blocked at 2 h prior to the incubation with Mito(T)-
pep-Nuc(T) with Ac-DEVD-CHO (final concentration: 0.2 nM), SB-3CT (final
concentration: 14 nM), CA-074 methyl ester (final concentration: 8 μM), and
chlorpromazine (10 μg mL−1), respectively. All these inhibitors were solubilized in
DMSO before their introduction into the culture medium of the cell.
Bioluminescence imaging. The onset/development of liver metastasis was mon-
itored using BLI. At each time point, the mouse received an intraperitoneal
injection of a PBS solution containing D-luciferin (200 mg kg−1). After 20 min, the
mouse was anesthetized with isoflurane via inhalation and imaged using an IVIS
200 system (PerkinElmer Imaging Systems, United States). Data were processed
and reconstructed on the workstation.
Immunofluorescent imaging. Freshly collected liver tissue was first embedded in
an optimal cutting temperature compound (Tissue-Tek, Sakura, United States) and
frozen on ice. Frozen blocks were sectioned to a thickness of 10 μm and mounted
onto glass slides. Blocking and hybridization were performed in 3.0% (wt/vol) BSA
in PBS. All images were acquired and processed the same as we did for fluorescence
imaging.
Long-term cytotoxicity. Antibody array assays were leveraged to evaluate the
inflammatory response (Inflammation cytokine array; Ray Biotech Inc., United
States) and were conducted according to the manufacturer’s instructions. In this
case, the liver metastasis bearing mice were sacrificed at Days 1 and 15 after the
treatments and minced into single-cell suspension using a 400-mesh screen within
1 h after the removal of the liver tissue. The suspension containing both body fluid
and cells was centrifugated, and the supernatant containing the inflammatory
cytokines was collected and stored at −80 °C prior to the microarray assay. For the
working principles as well as the data collection and subsequent analysis, please
refer to our previous publication34.
Normal female nude mice that had received an i.v. injection of Mito(T)-pep-
Nuc(T) nanoparticles (15 mg per mouse) were sacrificed on Days 1, 7, 15, and 30
post the injection. Both the pathological and hematological analyses were
conducted to assess the potential systematic toxicity caused by Mito(T)-pep-Nuc
(T). Specially, for pathological studies, four major organs, including lungs, liver,
spleen, and kidneys, were harvested at each time point, with their sections stained
with H&E. For the hematological study, peripheral blood was collected and stored
in a sodium EDTA anticoagulant tube (BD Bioscience, United States). Potential
cytotoxic and allergic effects were reflected by the variation of ALT, TP, total
bilirubin TBIL level, platelet, BUN, and creatinine (CRE) expressions.
To assess the potential complications associated with PDT alone, the mice
received the systematic injection of Mito(T)-pep-Nuc(T) (15 mg per mouse) were
irradiated with 633-nm laser (1W cm−2, 15 min).
Analyses of changes in gene and protein expression. Cancer cells metastasized
to the liver were collected via the flow-cytometry sorting, followed by their
extraction of total RNA and proteins that serve as the materials for gene expression
and proteome analyses, respectively. The changes in gene expression were eval-
uated using a microarray (SurePrint G3 array v2.0 8 × 60k for human; Agilent
Technologies, United States) according to the manufacturer’s instructions. The
changes of protein expression were assessed using quantitative LC/MS based on
TMT-labeling (a coupled system of QExactive mass spectrometer and the Easy
Nano LC; Thermo Fisher Scientific). Peptides were detected with a well-established
top-20 method in an Orbitrap mass spectrometer equipped with a hybrid dual-cell
quadrupole linear ion trap (LTQ Orbitrap Elite; Thermo Fisher Scientific). The
obtained MS2 spectra were searched using the SEQUEST algorithm (version 28)57,
with the possible positively expressed proteins listed, whose sequences matched
with that of those existed human-originated proteins (Homo sapiens) as displayed
in the database. By taking a collective consideration of false discovery rate and p
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value calculated based on independent tests, those proteins with changes in
expression levels as reflected by absolute fold change greater than 1.2 were chosen
for bioinformatic analyses. For the differently expressed genes or proteins, GO
analysis was performed using OmicsBean Cancer in order to better understand the
molecular mechanism underlying the therapeutic effect exerted by different
treatments.
Statistics. Triplicate data were analyzed with Student’s t-test and one-way
ANOVA using GraphPad Prism software (version 7.0); the significance level was
set at p < 0.05. Significant statistical differences are indicated by asterisks in cor-
responding figures.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available in the
article and associated Supplementary Information. Extra data or information are
available from the corresponding authors upon reasonable request.
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